



# Rutherford HEALTH plc

Proton Beam Therapy

The total number of shares in issue is 197,973,238.

The total voting rights ("TVR") is 175,088,472\*.

Shareholders will be notified of any change in TVR (whether arising as a result of changes in the issued share capital or the application of limitations on the voting rights of certain shareholders) and should use the notified TVR number as the denominator in calculating their voting rights for the purposes of DTR 5.

As at Admission, there are CSOP options outstanding over 4,552,826 Ordinary Shares. Upon exercise in full, such options would represent 2.3 percent of the fully diluted issued share capital.

Substantial Shareholders Following Admission		
Shareholder	Number of Ordinary Shares	Percentage of Share Capital
NorTrust Nominees Limited <sup>(1)</sup> (Account WIX01)	57,027,019	28.8%
NorTrust Nominees Limited <sup>(2)</sup> (Account WIZ01)	52,136,364	26.3%
Cruisen Ltd	14,500,000	7.3%
The Wales Life Sciences Investment Fund LP	10,000,000	5.1%
Global Healthcare Limited	7,000,000	3.5%
Smart Profit Limited	6,956,522	3.5%
WND Holding Ltd	6,956,522	3.5%

1. LF Equity Income Fund
2. Schroder UK Public Private Trust PLC

\* Due to the limitation on voting rights applying to the holding of LF Equity Income Fund, as described in more detail in the Admission Document dated 25 February 2019.